Pherecydes Pharma Obtains ANSM Approval for its PhagoDAIR Program, the World's First Study in Precision Phage Therapy Seite 1

22.12.2021 - Regulatory News: Pherecydes Pharma (FR0011651694 – ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that it has obtained ANSM (French ... Seite 1

Related Keywords

France ,Spain ,Pherecydes Pharma ,Patient Protection Committee ,Implant Retention ,Protection Committee ,Pherecydes Pharma Sadir ,